Almost 90% of pancreatic cancers are driven by oncogenic mutations of Kras. Aberrant Kras signaling activates inflammatory signaling pathways that play critical roles in regulating the initiation of pancreatic intraepithelial neoplasia (PanIN) and the progression of PDAC [53]. Here, KRAS is linked to pancreatic neoplasm.